Mears, Jennifer
Kaleem, Safa
Panchamia, Rohan
Kamel, Hooman
Tam, Chris
Thalappillil, Richard
Murthy, Santosh
Merkler, Alexander E.
Zhang, Cenai
Ch’ang, Judy H. http://orcid.org/0000-0001-9017-9830
Article History
Received: 6 July 2023
Accepted: 1 February 2024
First Online: 20 March 2024
Conflicts of interest
: Mears: none. Kaleem: none. Panchamia: none. Kamel: Dr. Kamel serves as a principal investigator for the National Institutes of Health–funded AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA) trial (National Institute of Neurological Disorders and Stroke grant U01NS095869), which receives in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; serves as Deputy Editor for <i>JAMA Neurology</i>; serves on clinical trial steering/executive committees for Medtronic, Janssen, and Javelin Medical; serves on end point adjudication committees for AstraZeneca, Novo Nordisk, and Boehringer Ingelheim; and has an ownership interest in TETMedical, Inc. Tam: none. Thalappillil: none. Murthy: none. Merkler: Dr. Merkler serves as an expert witness for medicolegal cases. Zhang: none. Ch'ang: none.
: The Weill Cornell Medicine Institutional Review Board approved this ambidirectional analysis of data collected as part of the quality initiative.